@prefix this: . @prefix sub: . @prefix np: . @prefix pav: . @prefix rdf: . @prefix infores: . @prefix xsd: . @prefix orcid: . @prefix rdfs: . @prefix biolink: . @prefix prov: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubInfo; a np:Nanopublication . } sub:assertion { a biolink:ChemicalEntity; rdfs:label "tenofovir"; biolink:category biolink:ChemicalEntity . a biolink:ChemicalEntity; rdfs:label "emtricitabine"; biolink:category biolink:ChemicalEntity . a biolink:ChemicalEntity; rdfs:label "Efavirenz"; biolink:category biolink:ChemicalEntity . a biolink:DiseaseOrPhenotypicFeature; rdfs:label "HIV-1 infection"; biolink:category biolink:DiseaseOrPhenotypicFeature . sub:_1 rdf:object ; rdf:predicate biolink:treats; rdf:subject ; a biolink:Association; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:Association; biolink:publications . sub:_2 rdf:object ; rdf:predicate biolink:treats; rdf:subject ; a biolink:Association; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:Association; biolink:publications . sub:_3 rdf:object ; rdf:predicate biolink:treats; rdf:subject ; a biolink:Association; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:Association; biolink:publications . } sub:provenance { sub:assertion prov:generatedAtTime "2022-10-13T12:23:04.110997"^^xsd:dateTime; prov:wasAttributedTo orcid:0000-0002-3668-2627; prov:wasQuotedFrom " Efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets are indicated as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg. The tablets are available as a combination or complete regimen for adults and children weighing more than 40 kg." . biolink: pav:version "2.3.0" . } sub:pubInfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIIBIjANBgkqhkiG9w0BAQEFAAOCAQ8AMIIBCgKCAQEApdULbl+/+pkVlq0fAzWmzfgIb+XMuQPKHMDVzUTWCZBjLfzORll42ptr52e4w7tTYkUKrBsQbx8lkjZWAlWiyh+xIK0oLFSdYRSt63kgiyRYBUOR+spcgmofb7f6JyftArPVTKhsWOMt/mcyNG9qc3lw8B/xuPmLteUWO33xWhfXQreTw1lsGUkZ1j4cB4X9HIuI20ktLYLCXaBauNHEJZ4qp6/Q2ATsJcw8tg7aRmFKXhrjM9maZ2+0cMg0Jpmn2UnDlPKXEA6Qq+qnvvQt8KFjIzP9FTMyvrWl8tTd0NCmS9VpooZJQ8We1lGMPXg5bMbe/bVkTf70fbFMf0RKrQIDAQAB"; npx:hasSignature "mdkpguvXLaxyWlvhT5XgFzNh4/mZMCaVKYRi9v9oLJP45Kirf6t7veNS6Lc/saAuMkuQcXrjvnSbfZ2TK2afQBSi1Y9XdXiRucuHPCWy+x16MJP94jQ2Evh2wPymcFinXlw2td9rTBjGMcMBHdAvjS9m5s3hBGiW9jD6sJSCJqcvPtlorOIUpgpLwnjfxeUFIOBRrgh6hJQNjRSLu59on+kpHew86b/kI6xUL87pOOvdg+gl8qK1f3B708kbNukAxKFMaSgb7bcroR9WCf43khaw2ZuFKjePWAK/GNtmlPuIC/2og3aB/hXpBILazaE/DttHdELfZHXfXbagmM5NEA=="; npx:hasSignatureTarget this: . this: prov:generatedAtTime "2022-10-13T12:23:04.110997"^^xsd:dateTime; prov:wasAttributedTo orcid:0000-0002-3668-2627 . }